Moderna, Inc. (MRNA) Dividend History

Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.

325 Binney Street, Cambridge, MA, 02142
Phone: (617) 714-6500
Website: https://www.modernatx.com

Dividend History

Moderna, Inc. currently does not pay dividends

Company News

  • Moderna's mRNA Flu Vaccine Outperforms Standard Shots

    Moderna reported positive Phase 3 trial results for its mRNA-1010 flu vaccine, showing 26.6% higher efficacy compared to standard flu shots in adults over 50, with mild adverse reactions and strong performance across different influenza strains.

    Benzinga
    Featured Companies: NVAX
  • Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges

    The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.

    GlobeNewswire Inc.
    Featured Companies: ARCT CVAC PFE
  • Is it Time to Dump Your Shares of Moderna?

    Moderna, a biotech company, has experienced a reversal of fortune after its COVID-19 vaccine success. Despite positive news, such as the approval of a second product and progress on cost cuts, the stock has remained in the doldrums. However, the company's impressive late-stage pipeline and potential product launches on the horizon could lead to a significant revenue boost and a stock price recovery in the long run.

    The Motley Fool
  • MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

    Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.

    Zacks Investment Research
    Featured Companies: MRK SMMT
  • Moderna Stock Looks Ripe for a Short Squeeze

    Moderna stock has fallen over 80% in the last 12 months, but options activity and short interest suggest a potential short squeeze. The company's mRNA technology and pipeline remain promising, despite recent setbacks.

    Investing.com
    Featured Companies: MRK

Related Companies

Page data last updated 07/02/2025 01:53:54 UTC